Vanta Holdings (VNTXF) closed the final tranche of its private placement on October 15, 2026, raising $210,000 in gross proceeds. It issued 210,000 units at $1.00 each, comprising one common share and one warrant exercisable at $1.25 until October 15, 2028. Total placement gross proceeds reached C$334,579.42. Vanta paid $1,500 in cash finder's fees for the second tranche. Net proceeds are intended for outstanding and future payables and indebtedness, including related-party amounts, and corporate awareness.
Vanta also welcomed the October 14 launch of the REX Peptide ETF, but has no affiliation with the fund or its sponsor. Its planned U.S. peptide platform has an operating framework agreement through subsidiary Vanta Amino Sciences. Commercialization remains subject to adequate funding, regulatory compliance and definitive commercial agreements, as applicable.
Vanta Holdings (VNTXF) reports its representatives attended the 2026 All-In Summit in Los Angeles from September 13-15, 2026.
Over the three-day event, the team met founders, investors, executives and healthcare and technology participants to build relationships, discuss emerging technologies and explore potential strategic collaboration and business development opportunities. Company representatives also connected with participants in the peptide therapeutics and broader healthcare ecosystem in support of Vanta’s planned U.S.-focused peptide therapy platform, which is intended to integrate telehealth, physician consultation, pharmacy fulfillment and subscription-based commercialization initiatives.
Vanta Holdings (CSE:VNTA, OTC:VNTXF) has engaged Independent Trading Group (ITG) to provide CSE-compliant market-making services for its common shares, effective August 27, 2026. The engagement is part of Vanta’s strategic capital markets initiatives to enhance trading liquidity, support orderly markets, and improve overall market quality.
The agreement runs for an initial one-month term, automatically renewing monthly unless terminated with 30 days’ notice. Vanta will pay ITG $6,000 per month plus taxes in cash, with no share- or option-based compensation and no performance factors. Vanta describes ITG as an arm’s length CIRO dealer-member, with no known equity interest in the company.
Vanta Holdings (CSE:VNTA, OTC:VNTXF) closed the first tranche of its previously announced non-brokered private placement, issuing 124,579 units at $1.00 per unit for gross proceeds of $124,579.42. Each unit includes one common share and one transferable warrant exercisable at $1.25 until August 21, 2028, subject to a hold period expiring December 22, 2026. The private placement remains open, with further tranches expected on or before October 5, 2026, subject to Canadian Securities Exchange policies.
Vanta also reported that Norman John Campbell resigned from the board effective August 21, 2026, reducing the board to four members, comprising two independent and two non-independent directors.
Vanta (CSE:VNTA, OTC:VNTXF) reports that the U.S. FDA Pharmacy Compounding Advisory Committee voted on July 23–24, 2026 to recommend inclusion of six peptide substances — BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax — on the FDA's 503A Bulks List. The recommendation is advisory, and the FDA will make the final determination, which would define whether 503A compounding pharmacies may use these substances in customized medications under U.S. law.
Vanta highlights a strategic framework for a contemplated U.S. peptide platform, supported by its Strategic Peptide Operating Partner under a master services and commercialization agreement. This framework covers telehealth-enabled commercialization, coordination with FDA-registered 503A/503B compounding pharmacies, peptide manufacturing and fulfillment, and compliant payment processing. Vanta aims to integrate the planned peptide platform with its existing nutraceutical and premium functional hydration portfolio into a longevity-focused consumer health sciences platform. The company has not yet begun U.S. peptide sales and estimates about C$850,000 of initial capital will be required for launch and early scaling, with the project subject to financing, regulatory and execution risks.
Vanta (OTC:VNTXF) announced a five-year exclusive global brand partnership and master distribution agreement with Animal Spirits' PickelBall Pixels (PBX). Vanta will be the exclusive worldwide manufacturer and supplier of PBX-branded products using Vanta Blackwater formulations, with minimum purchase commitments totaling US$8 million, while retaining all Blackwater IP and its own-brand commercialization rights.
Vanta (OTC:VNTXF) announced that subsidiary Naturo Group received a Distillery Manufacturer Licence from the British Columbia Liquor and Cannabis Regulation Branch.
The licence enables commercial spirits production at Vanta's 40,000-square-foot Bridesville facility, expanding contract manufacturing, co-packing and product development across spirits, RTDs, wines, coolers and better-for-you adult beverages, and may diversify revenue streams.
Vanta (OTC:VNTXF) announced a proposed non-brokered private placement of up to 2,500,000 units at $1.00 per unit, for gross proceeds up to $2.5 million. Each unit includes one share and one warrant exercisable at $1.25 for 24 months.
According to Vanta, net proceeds will fund its integrated longevity and consumer health sciences platform, including planned U.S. peptide market entry, product commercialization, business development, paying outstanding payables and indebtedness, corporate awareness, and working capital. Closing is targeted on or about June 30, 2026, with securities subject to a four‑month‑plus‑one‑day hold.
Vanta (OTC:VNTXF) entered a three-year master services and strategic operations agreement, effective May 28, 2026, to support a proposed U.S.-focused peptide therapy and longevity platform. The strategic partner coordinates FDA-registered 503A/503B pharmacy access, telehealth infrastructure, and compliant online and in-person payment processing.
The contemplated platform targets subscription-based peptide, nutraceutical, and premium hydration offerings within U.S. peptide therapeutics and longevity markets projected to grow at double-digit CAGRs. Vanta estimates about CAD$850,000 of startup capital for commercial launch and early-stage scaling.
Vanta (OTC:VNTXF) closed the second tranche of a non‑brokered private placement on May 6, 2026, issuing 615,000 units at $1.00 per unit for gross proceeds of $615,000, bringing aggregate raises to $1,000,000.
Each Unit includes one common share and one warrant exercisable at $1.25 until May 6, 2028. Net proceeds are intended for payables (including related parties), corporate awareness, inventory, and working capital. Securities are subject to a statutory hold expiring September 7, 2026.